Developing a peptide-based oral drug to prevent kidney stones
Ended Project Grant Awarded Last action
- Award ID
- R42DK120261
- Recipient
-
Oxalo Therapeutics UEI JD11RKB2KWJ3
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,299,991
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Place of performance
- Illinois, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $999,995 | |
| Amendment | $5,474 | |
| Amendment | -$5,474 | |
| Amendment | $0 | |
| Amendment | $999,998 | |
| Amendment | $0 | |
| Original award | $299,998 |
Show all 15
Quick answers
Who received award R42DK120261?
R42DK120261 was awarded to Oxalo Therapeutics by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 19, 2018.
How much is award R42DK120261 worth?
$2,299,991 has been obligated on R42DK120261.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award